- 全部删除
您的购物车当前为空
Ensartinib hydrochloride (X-396 dihydrochloride) 是双重的 ALK/MET 抑制剂,IC50分别 <0.4 nM 和 0.74 nM。

Ensartinib hydrochloride (X-396 dihydrochloride) 是双重的 ALK/MET 抑制剂,IC50分别 <0.4 nM 和 0.74 nM。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 496 | In stock | |
| 2 mg | ¥ 733 | In stock | |
| 5 mg | ¥ 1,230 | In stock | |
| 10 mg | ¥ 1,990 | In stock | |
| 25 mg | ¥ 3,970 | In stock | |
| 50 mg | ¥ 5,850 | In stock | |
| 100 mg | ¥ 8,120 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 1,730 | In stock |
Ensartinib hydrochloride 相关产品
| 产品描述 | Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known crizotinib-resistant ALK mutations. It potently inhibits both wild-type ALK and ALK variants (C1156Y, F1174, G1202R, L1196M, S1206R, and T1151 mutants) with in vitro IC50s of <4 nM. |
| 靶点活性 | TrkC:<1 nM, TPM3-TRKA:<1 nM, ALK:<4 nM, ALK (variants):<4 nM, GOPC-ROS1:<1 nM |
| 体外活性 | Ensartinib potently inhibits both wild-type ALK and all evaluated ALK variants (C1156Y, F1174, G1202R, L1196M, S1206R, and T1151 mutants) with in vitro IC50s of <4 nM. Besides ALK, ensartinib also potently inhibits GOPC-ROS1, TPM3-TRKA, and TRKC with an IC50 of <1 nM, and inhibits EphA1, EphA2, EphB1 and c-MET with an IC50 of 1-10 nM[1]. |
| 别名 | X-396 dihydrochloride, Ensartinib dihydrochloride |
| 分子量 | 634.36 |
| 分子式 | C26H29Cl4FN6O3 |
| CAS No. | 2137030-98-7 |
| Smiles | Cl.Cl.C[C@@H](Oc1cc(nnc1N)C(=O)Nc1ccc(cc1)C(=O)N1C[C@H](C)N[C@H](C)C1)c1c(Cl)ccc(F)c1Cl |
| 密度 | no data available |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 33 mg/mL (52.02 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
评论内容